Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 18/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366467 | 0.93 | SLC8A1 (0.53) | SLC8A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4368895 | 0.92 | SLC8A1 (0.48) | SLC8A1 | |
| SCHEMBL4362119 | 0.90 | SLC8A1 (0.50) | SLC8A1MAP2K7 | |
| SCHEMBL4374177 | 0.89 | SLC8A1 (0.54) | SLC8A1 | |
| SCHEMBL4364002 | 0.89 | SLC8A1 (0.45) | SLC8A1MAP2K7KDM4EMEN1MAPT | |
| SCHEMBL4367092 | 0.89 | SLC8A1 (0.47) | SLC8A1 | |
| SCHEMBL4358815 | 0.89 | SLC8A1 (0.47) | SLC8A1 | |
| SCHEMBL4358798 | 0.88 | SLC8A1 (0.48) | SLC8A1 | |
| SCHEMBL4363696 | 0.87 | SLC8A1 (0.44) | SLC8A1 | |
| SCHEMBL4372528 | 0.87 | SLC8A1 (0.41) | SLC8A1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | SLC8A1 5/4885MAP2K7 2679/4885KDM4E 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.